Concurrent Sorafenib and Radiotherapy versus Radiotherapy Alone for Locally Advanced Hepatocellular Carcinoma: A Propensity-Matched Analysis

PURPOSE: Evidence is lacking concerning the benefit of the combination of sorafenib and radiotherapy to treat advanced hepatocellular carcinoma (HCC). To date, no publication has reported the outcomes of radiotherapy alone versus concurrent therapy. We aimed to compare the effectiveness of radiother...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Chieh-Min, Huang, Bing-Shen, Yen, Yi-Hao, Wang, Yu-Ming, Huang, Eng-Yen, Hsu, Hsuan-Chih, Huang, Tzu-Ting, Yang, Yao-Hsu, Cheng, Jen-Yu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8380802/
https://www.ncbi.nlm.nih.gov/pubmed/34434903
http://dx.doi.org/10.2147/JHC.S323302

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8380802/
https://www.ncbi.nlm.nih.gov/pubmed/34434903
http://dx.doi.org/10.2147/JHC.S323302

Ejemplares similares